Cannabis News

macbill

macbill

Oh No! Mr macbill!!
Staff member
Cannabis conversation urged at North American Leaders Summit

At the end of this week, President Barack Obama, Canadian Prime Minister Justin Trudeau, and Mexican President Enrique Pena Nieto will meet in Ottawa for the North American Leaders’ Summit. Since the summit was first convened in 2005, this regular gathering has been used to discuss shared economic and security issues, like trade and resource management. This year, however, these three leaders have a unique chance to address the future of an industry that will be among the defining political and economic forces of the next ten years, if not the next fifty. That industry is legal cannabis.
 
C No Ego

C No Ego

Well-Known Member
Gunky said:
The pharmaceutical companies want a cash cow that they can sell you lots of and that you can't make at home. If they had their druthers they would also prefer to fix prices at a high point and eliminate all competition. Not saying they are necessarily evil but big corporations go after profit so naturally some of their interests come into conflict with the interests of ordinary cannabis consumers. This is why it is so important and strategic to always insist upon legislation and initiatives that include legal home grows. If there is an alternative and competition to cannabis products provided by big corporations, this will help keep some of their greedy, less wholesome, and monopolistic instincts in check.
Click to expand...

the last fight for humans not to become robots is to have access to plants and not be incarcerated for choosing plants over man made substances( synthetically remade from plants) . The creator of plants made plants and Humans so.... lets trust the creator of all things instead of man made things, logic reasoning or blind faith.... Oh, and the last fight for prohibitionists is to prove plants are bad to justify their harsh approach but they have come up with zilch.
 
SSVUN~YAH

SSVUN~YAH

You Must Unlearn, What You Have Learned...
Ex-Raven Eugene Moore wants the NFL to back medical marijuana. He also wants to grow it.

Former Baltimore Ravens lineman Eugene Monroe delighted marijuana advocates and irked the National Football League in March when he became an outspoken advocate of medical pot.

In a steady stream of media interviews, the imposing 29-year-old bemoaned the frequent injuries that come with tackling 300-pound men for a living, and he laid into the NFL for what he called an over reliance on opiates in treating chronic pain. He publicly pressured the league to recognize marijuana as a viable painkiller and announced that he was donating $80,000 to medical-marijuana research

What Monroe did not say was that he had a direct financial stake in seeing the drug go mainstream.

Documents obtained by The Washington Post from the state of Maryland show that Monroe has a share worth at least 5 percent in Green Thumb Industries (GTI), one of 144 companies seeking a license to grow medical marijuana in Maryland.

Monroe declined to say how much money he has invested in GTI Maryland, the local outpost of the company that operates massive grow houses in Illinois and has licenses in Nevada. He agreed to invest in August and says he has no plans to invest in other marijuana companies.

"Right now, I've made a decision to invest with GTI, and I guess that's all I'll talk about right now," Monroe said in an interview. He described the investment as a vehicle to help make medical pot commercially viable.

"People across our country, and especially athletes, need access to medical cannabis," Monroe said. "I think my investment in GTI represents my commitment to helping make this possible for people."

The Ravens organization may see it somewhat differently. Earlier this month, the team released Monroe from his $37.5 million contract. He had been injured and unable to play for the better part of two years, despite collecting the highest base salary of any player on the team. An article posted on the team's website appeared to chide Monroe's advocacy efforts.

"Monroe had surgery to repair a torn labrum (shoulder) this offseason, and used the time off to become the first active NFL player to openly campaign for the use of medical marijuana," the article said. "The Ravens did not rally behind his cause."

Neither the team nor the NFL Players Association responded to requests for comment. Monroe says he never told the Ravens about his investment with GTI.

"I don't consult with the NFL or the Baltimore Ravens on any of my decisions to invest in any company," he said, "and I don't see any reason why my advocacy for medical cannabis would impact my playing career with the Ravens."

GTI chief executive Pete Kadens said the company never asked Monroe to be a public advocate for medical pot. Kadens recalled being surprised when the player's name started popping up in news reports.


"[Monroe] said to me, 'I believe this. It's part of me, it's part of my core, and I just can't care what the ramifications are at this point. I have to do this,' " Kadens said.

There are other athletes among the hundreds of individuals teaming up to seek licenses to grow medical marijuana in Maryland.

Real estate executive Kevin Gibbs, a District of Columbia native who played baseball for the Los Angeles Dodgers and the New York Yankees, is an investor in prospective grower Peak Harvest Health. Darryl Hill, who is heading up a team of investors applying as Tilstar LLC, was recognized by the Maryland legislature for being the first African American to play football at the University of Maryland. And Dennis DuVal, a former Syracuse, New York, police chief who is a principal at Citiva Maryland, had a brief stint with the Washington Bullets in the 1970s.

http://www.chicagotribune.com/business/ct-eugene-monroe-nfl-medical-marijuana-20160627-story.html
 
BD9

BD9

Well-Known Member
Bad news from the Supreme Court for Montana medical MJ users and dispensaries.

Montana

Medical marijuana

The court won't hear an appeal challenging a Montana law that limits medical marijuana providers to selling the drug to a maximum of three patients each.

The justices let stand a Montana Supreme Court ruling that upheld key provisions of a state law that rolled back much of the 2004 voter-approved initiative legalizing medicinal marijuana.

The Montana Cannabis Industry Association said the rollbacks would force the closure of dispensaries and leave patients without a legal way to obtain the drug.
 
C No Ego

C No Ego

Well-Known Member
waxdab23 said:
Show me the money...

CNBC: There's a new gold rush in California as investors prep for pot ... http://www.cnbc.com/2016/06/30/ther...investors-prep-for-pot-legalization-vote.html
Click to expand...

terrible that all these people are fueling their desires to get rich off the back of black market risk based price gouging of the American populace. a new market should mean new price regulatory schemes not in line with black market anything. I guess enough people will eventually realize that and enough is enough...
 
yogoshio

yogoshio

Annoying Libertarian
Whenever you hear the term "regulatory" when it comes to pricing, there is always a scheme. There is always economic loss when that happens.
 
yogoshio,
  • Like
Reactions: C No Ego
macbill

macbill

Oh No! Mr macbill!!
Staff member
Marijuana Compound Removes Alzheimer’s-Related Protein From Nerve Cells
With the prevalence of Alzheimer’s disease expected to almost triple in the United States by 2050, there is an urgent need to identify effective treatments for the condition.

Now, a new study suggests marijuana may hold the key to such a treatment.

Published in the journal Aging and Mechanisms of Disease, the study reveals how a compound present in marijuana triggered the removal of beta-amyloid protein from nerve cells, or neurons.
*************************
Heh, my brain is swimming in that....
 
looney2nz

looney2nz

Research Geek, Mad Scientist
macbill said:
Marijuana Compound Removes Alzheimer’s-Related Protein From Nerve Cells
With the prevalence of Alzheimer’s disease expected to almost triple in the United States by 2050, there is an urgent need to identify effective treatments for the condition.

Now, a new study suggests marijuana may hold the key to such a treatment.

Published in the journal Aging and Mechanisms of Disease, the study reveals how a compound present in marijuana triggered the removal of beta-amyloid protein from nerve cells, or neurons.
*************************
Heh, my brain is swimming in that....
Click to expand...

this study was specific to THC, I wonder if they have another study working on CBD?
 
cybrguy

cybrguy

Putin is a War Criminal
macbill said:
Marijuana Compound Removes Alzheimer’s-Related Protein From Nerve Cells
With the prevalence of Alzheimer’s disease expected to almost triple in the United States by 2050, there is an urgent need to identify effective treatments for the condition.

Now, a new study suggests marijuana may hold the key to such a treatment.
Click to expand...
Very promising research. This is an area that could yield fascinating new knowledge. Kind of exciting to those of us who have family members who have been effected.
 
macbill

macbill

Oh No! Mr macbill!!
Staff member
One striking chart shows why pharma companies are fighting legal marijuana

imrs.php
 
F

farscaper

Well-Known Member
macbill said:
One striking chart shows why pharma companies are fighting legal marijuana

imrs.php
Click to expand...

And this... it's easier to patent a synthetic drug...

Regulators at the US Food and Drug Administration for the first time have approved the prescription of a liquid form of dronabinol (synthetic THC), to be marketed under the trade name Syndos.

The new drug formula, produced by Insys Therapeutics, is approved for use in patients with AIDS (as an appetite stimulant) and cancer (as an antiemetic).

The pharmaceutical provider is anticipated to publically launch the drug in the second half of this year.

The FDA initially approved the prescription use of dronabinol as an oral pill, marketed under the trade name Marinol, in 1985. Marinol is currently classified as a Schedule III controlled substance under the Controlled Substances Act. The prescription drug remains relatively unpopular with patients and physicians, largely because of its delayed onset, high degree of bioavailability, and potential dysphoric side effects, which tend to be far more pronounced than those associated with inhaled cannabis.

A separate synthetic cannabinoid drug, nabilone (trade name Cesamet), received FDA approval for use by prescription in 2006.

Insys Therapeutics previously received orphan drug approval status from the FDA in 2014 for a pharmaceutical formulation of cannabidiol (CBD).

(What the fuck is "orphan drug approval status" mean?)

The above information came directly from NORML newsletter.
 
C No Ego

C No Ego

Well-Known Member
farscaper said:
And this... it's easier to patent a synthetic drug...

Regulators at the US Food and Drug Administration for the first time have approved the prescription of a liquid form of dronabinol (synthetic THC), to be marketed under the trade name Syndos.

The new drug formula, produced by Insys Therapeutics, is approved for use in patients with AIDS (as an appetite stimulant) and cancer (as an antiemetic).

The pharmaceutical provider is anticipated to publically launch the drug in the second half of this year.

The FDA initially approved the prescription use of dronabinol as an oral pill, marketed under the trade name Marinol, in 1985. Marinol is currently classified as a Schedule III controlled substance under the Controlled Substances Act. The prescription drug remains relatively unpopular with patients and physicians, largely because of its delayed onset, high degree of bioavailability, and potential dysphoric side effects, which tend to be far more pronounced than those associated with inhaled cannabis.

A separate synthetic cannabinoid drug, nabilone (trade name Cesamet), received FDA approval for use by prescription in 2006.

Insys Therapeutics previously received orphan drug approval status from the FDA in 2014 for a pharmaceutical formulation of cannabidiol (CBD).

(What the fuck is "orphan drug approval status" mean?)

The above information came directly from NORML newsletter.
Click to expand...

let the synthetics Roll! humans will soon be hard wired and yes, we will have synthetic humans just like we are synthesizing everything else. maybe synthetic humans will be able to benefit from synthetic drugs. the real humans will stick with the real thing....
 
cybrguy

cybrguy

Putin is a War Criminal
farscaper said:
(What the fuck is "orphan drug approval status" mean?)
Click to expand...
From Wikipedia, the free encyclopedia
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.

In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive.[1][2] The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.[3]
 
You must log in or register to reply here.
Top Bottom